Patents Issued in September 25, 2018
-
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
Patent number: 10080766Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.Type: GrantFiled: September 13, 2016Date of Patent: September 25, 2018Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen -
Patent number: 10080767Abstract: An injectable monophase hydrogel is provided and is made of a reaction mixture of a high molecular weight hyaluronic acid and a low molecular weight hyaluronic acid.Type: GrantFiled: July 13, 2016Date of Patent: September 25, 2018Assignee: Allergan Industrie SASInventor: Pierre F. Lebreton
-
Patent number: 10080768Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: GrantFiled: April 14, 2017Date of Patent: September 25, 2018Assignee: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Patent number: 10080769Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.Type: GrantFiled: October 27, 2016Date of Patent: September 25, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Samuel Strober, Robert Lowsky
-
Patent number: 10080770Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.Type: GrantFiled: September 29, 2017Date of Patent: September 25, 2018Assignee: RegenLab USA LLCInventors: Antoine Turzi, Donald Francois Du Toit
-
Patent number: 10080771Abstract: Compositions and methods for generating human epithelial stem cells from induced pluripotent stem cells are disclosed. Also disclosed are methods of using cells so generated in hair transplant procedures.Type: GrantFiled: January 28, 2016Date of Patent: September 25, 2018Assignee: The Trustees of the University of PennsylvaniaInventors: Xiaowei Xu, Ruifeng Yang
-
Patent number: 10080772Abstract: The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.Type: GrantFiled: March 8, 2018Date of Patent: September 25, 2018Assignee: 4D Pharma PLCInventors: Laureen Crouzet, Chloe Habouzit, Annick Bernalier-Donadille
-
Patent number: 10080773Abstract: A probiotic organism which is capable of proliferation in iron-rich media, an environment which is generally unfavorable to probiotic organisms, is described.Type: GrantFiled: July 19, 2012Date of Patent: September 25, 2018Assignee: The University of BristolInventors: Tristan Cogan, Jenny Bailey
-
Patent number: 10080774Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.Type: GrantFiled: May 4, 2015Date of Patent: September 25, 2018Assignee: Board of Regents, The University of Texas SystemInventors: Juan Fueyo, Candelaria Gomez-Manzano, W. K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
-
Patent number: 10080775Abstract: A peptide having skin-whitening activity is described. The peptide exhibits an excellent skin whitening effect by inhibiting melanogenesis, inhibiting the activity of tyrosinase, inhibiting the expression of melanosis-involved factors, and inhibiting melanosome transfer. The peptide has excellent skin permeability due to the small size thereof. Excellent activity and stability of the foregoing peptide can be very favorably applied to cosmetics.Type: GrantFiled: February 6, 2017Date of Patent: September 25, 2018Assignee: CAREGEN CO., LTD.Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee, Jan Di Kim
-
Patent number: 10080776Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.Type: GrantFiled: May 24, 2016Date of Patent: September 25, 2018Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
-
Patent number: 10080777Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion, or inhibiting scarring and/or pathologic neovascularization.Type: GrantFiled: December 12, 2016Date of Patent: September 25, 2018Assignee: Wisconsin Alumni Research FoundationInventor: Alan Rapraeger
-
Patent number: 10080778Abstract: Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (BDNF) that are neurotrophic and can modulate BDNF signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where BDNF levels are dysregulated.Type: GrantFiled: October 19, 2016Date of Patent: September 25, 2018Assignee: Research Foundation For Mental Hygiene, Inc.Inventors: Khalid Iqbal, Inge Grundke-Iqbal
-
Patent number: 10080779Abstract: The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNF? and OSM that can be formulated for topical administration for cosmetic or dermatologic use.Type: GrantFiled: September 29, 2014Date of Patent: September 25, 2018Assignees: Universite D'Angers, Universite de Poitiers, Bioalternatives SASInventors: Jean-Claude Lecron, Hughes Gascan, Franck Morel, Sylvie Chevalier, Francois-Xavier Bernard, Katia Boniface, Caroline Diveau
-
Patent number: 10080780Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.Type: GrantFiled: October 5, 2016Date of Patent: September 25, 2018Assignee: Shire-NPS Pharmaceuticals, Inc.Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
-
Patent number: 10080781Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.Type: GrantFiled: October 5, 2016Date of Patent: September 25, 2018Assignee: Shire-NPS Pharmaceuticals, Inc.Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
-
Patent number: 10080782Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.Type: GrantFiled: June 9, 2010Date of Patent: September 25, 2018Assignee: Prolong Pharmaceuticals, LLCInventors: Abraham Abuchowski, Steven Sloshberg, Keith O'Hare
-
Patent number: 10080783Abstract: Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs.Type: GrantFiled: December 3, 2014Date of Patent: September 25, 2018Assignee: Genzyme CorporationInventors: James Dodge, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
-
Patent number: 10080784Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.Type: GrantFiled: February 20, 2012Date of Patent: September 25, 2018Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATIONInventors: William B. Parker, Eric J. Sorscher
-
Patent number: 10080785Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: October 29, 2007Date of Patent: September 25, 2018Assignee: NOVOZYMES BIOPHARMA DK A/SInventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Patent number: 10080786Abstract: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.Type: GrantFiled: November 9, 2015Date of Patent: September 25, 2018Assignee: REVANCE THERAPEUTICS, INC.Inventors: Michael D Dake, Jacob M Waugh
-
Patent number: 10080787Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomolecules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: GrantFiled: June 26, 2015Date of Patent: September 25, 2018Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Patent number: 10080788Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.Type: GrantFiled: December 11, 2017Date of Patent: September 25, 2018Assignee: Shire ViroPharma IncorporatedInventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
-
Patent number: 10080789Abstract: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.Type: GrantFiled: May 5, 2016Date of Patent: September 25, 2018Assignees: President and Fellows of Harvard College, Forsyth Dental Infirmary for ChildrenInventors: Roger Warren Sands, Eduardo Alexandre Barros E Silva, Toshihisa Kawai, David J. Mooney
-
Patent number: 10080790Abstract: The disclosure generally relates to the field of prevention and treatment of Staphylococcus aureus infections. In particular, the disclosure relates to immunogens comprising Staphylococcus aureus antigens and methods for generating immune responses to immunogens, and to antibody products specific for the Staphylococcus aureus epitopes and methods for treating Staphylococcus aureus infection with the antibody products.Type: GrantFiled: September 17, 2015Date of Patent: September 25, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jon Oscherwitz, Kemp Cease
-
Patent number: 10080791Abstract: The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions.Type: GrantFiled: September 11, 2015Date of Patent: September 25, 2018Assignee: MERIAL INC.Inventors: Nicolas Pierre Yves Carboulec, Rene Labatut, Lionel Gerentes
-
Patent number: 10080792Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.Type: GrantFiled: September 22, 2016Date of Patent: September 25, 2018Assignee: EnGen Bio, Inc.Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
-
Patent number: 10080793Abstract: The present invention relates to a method for prevention and/or reduction of aggregation of viral components.Type: GrantFiled: June 17, 2014Date of Patent: September 25, 2018Assignee: De Staat der Nederlanden, vert, door de minister van VWS, Ministerie van Volksgezonheid, Welzijn en SportInventors: Arend Gesinus van't Oever, Wilfridus Adrianus Maria Bakker, Yvonne Elisabeth Thomassen
-
Patent number: 10080794Abstract: Disclosed are compositions and methods comprising vectors and a reverse genetics competent unit comprising one or more recombinant influenza viruses. Recombinant influenza viruses comprising swine RNA polymerase I promoter are disclosed. Constructs comprising swine RNA polymerase I promoter nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus in swine.Type: GrantFiled: March 15, 2014Date of Patent: September 25, 2018Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Daniel R. Perez, Matthew Angel
-
Patent number: 10080795Abstract: The invention relates to a method for inactivating viruses, characterized in that an immunogenic composition or vaccine comprising at least one virus is irradiated with electron beams, said immunogenic composition or vaccine comprising at least one virus (i) being liquid, in particular being a suspension and (ii) comprising at least one viral immunogen, wherein the antigen structure is preferably substantially retained.Type: GrantFiled: July 25, 2014Date of Patent: September 25, 2018Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Sebastian Ulbert, Christiane Wetzel
-
Patent number: 10080796Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.Type: GrantFiled: May 6, 2016Date of Patent: September 25, 2018Assignee: TECHNOVAX, INC.Inventors: Jose M. Galarza, George R. Martin
-
Patent number: 10080797Abstract: Provided are an oncolytic heterologous recombinant Newcastle disease virus (NDV), preparation method and application thereof. The heterologous recombinant NDV can express alpha (1,3) galactosyltransferase (?1,3GT). The ?1,3GT is the protein represented by the flowing B1) and B2): B1) the protein has an amino acid sequence of SEQ ID No.1; and B2) the protein is derived from B1) and has a function of ?1,3GT obtained by substituting and/or deleting and/or adding one or more amino acid residue(s) in the amino acid sequence represented by SEQ ID No.1. The recombination NDV can be used for tumor treatment.Type: GrantFiled: August 23, 2016Date of Patent: September 25, 2018Inventor: Yongxiang Zhao
-
Patent number: 10080798Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.Type: GrantFiled: September 14, 2016Date of Patent: September 25, 2018Assignee: MERIAL INC.Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
-
Patent number: 10080799Abstract: Disclosed herein are compositions and methods for eliciting immune responses against HCV antigens. In particular embodiments, the compounds and methods elicit immune responses against all or a segment of HCV glycoprotein E1 and/or HCV glycoprotein E2.Type: GrantFiled: February 11, 2011Date of Patent: September 25, 2018Assignee: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: Hugh S. Mason, Seong Hee Bhoo, Sun Hee Rosenthal, Charles J. Arntzen
-
Patent number: 10080800Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).Type: GrantFiled: September 11, 2015Date of Patent: September 25, 2018Assignee: Novartis AGInventors: Winfried Elis, Seth Ettenberg, Andrew Paul Garner, Nicole Haubst, Xizhong Huang, Christian Carsten Silvester Kunz, Elizabeth Anne Reisinger Sprague, Qing Sheng
-
Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Patent number: 10080801Abstract: Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.Type: GrantFiled: October 7, 2014Date of Patent: September 25, 2018Assignee: Celgene CorporationInventors: Darshan Parikh, Anil Menon -
Patent number: 10080802Abstract: A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.Type: GrantFiled: January 13, 2016Date of Patent: September 25, 2018Assignee: Novartis AGInventors: Gossett Augustus Campbell, Helen Richardson, Peter A. Williams
-
Patent number: 10080803Abstract: Oil-in-water emulsions are prepared using phospholipids purified from krill.Type: GrantFiled: April 24, 2015Date of Patent: September 25, 2018Assignee: Aker BioMarine Antartic ASInventor: Stefan Hupfeld
-
Patent number: 10080804Abstract: Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate.Type: GrantFiled: December 15, 2016Date of Patent: September 25, 2018Assignee: ETHRIS GMBHInventors: Carsten Rudolph, Johannes-Peter Geiger
-
Patent number: 10080805Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.Type: GrantFiled: February 22, 2013Date of Patent: September 25, 2018Assignee: Purdue Research FoundationInventors: Philip S. Low, Charity Wayua
-
Patent number: 10080806Abstract: Polythioaminal polymers are made from hexahydrotriazine precursors and dithiol precursors. The precursors are blended together and subjected to mild heating to make the polymers. The polymers have the general structure wherein each R1 is independently an organic or hetero-organic group, each R2 is independently a substituent having molecular weight no more than about 120 Daltons, X and Z are each a sulfur-bonded species, at least one of X and Z is not hydrogen, and n is an integer greater than or equal to 1. X and Z may be hydrogen or a functional group, such as a thiol-reactive group. The reactive thiol groups of the polythioaminal may be used to attach thiol-reactive end capping species. By using water soluble or water degradable dithiols, such as polyether dithiols, water soluble polythioaminals may be made. Some such polymers may be used to deliver therapeutics with non-toxic aqueous degradation products.Type: GrantFiled: August 19, 2015Date of Patent: September 25, 2018Assignee: International Business Machines CorporationInventors: Dylan J. Boday, Willy Chin, Jeannette M. Garcia, James L. Hedrick, Xiyu Ke, Rudy J. Wojtecki, Yi Yan Yang
-
Patent number: 10080807Abstract: The present invention is based on a finding of an unexpected synergistic and safe combination of antineoplastic agents which when administered in combination provides greater efficacy than the single agents alone. Accordingly, a method of treating neoplasia in a subject in need of treatment is provided, by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C, in combination with an amount of a chemotherapeutic agent. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin C. Together, the prodrug of mitomycin C and chemotherapeutic agent provide a synergistic antineoplastic effect.Type: GrantFiled: June 9, 2015Date of Patent: September 25, 2018Assignees: Lipomedix Pharmaceuticals Ltd., Shaare Zedek Scientific Ltd.Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
-
Patent number: 10080808Abstract: This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.Type: GrantFiled: February 15, 2017Date of Patent: September 25, 2018Assignee: UTI LIMITED PARTNERSHIPInventor: Pedro Santamaria
-
Patent number: 10080809Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5?UTR element which is derived from a TOP gene, at least one open reading frame and optionally at least one 3?UTR element comprising a nucleic acid sequence which is preferably derived from the 3?UTR of a gene providing a stable mRNA, such as an albumin gene, or from a variant of the 3?UTR of a gene providing a stable mRNA. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.Type: GrantFiled: March 27, 2013Date of Patent: September 25, 2018Assignee: CureVac AGInventor: Andreas Thess
-
Patent number: 10080810Abstract: A method for testing, treating, and preventing delayed food allergies includes: receiving detailed symptom, medical, and dietary histories from a patient; formulating a combination of one or more food extracts at selected concentrations for sublingual administration over a trial period; determining whether the patient's symptoms have improved, worsened, or had no change, in response to the administration of the combination; and altering the combination in response to whether the patient's symptoms have improved, worsened, or not changed, so as to induce immune system food tolerance.Type: GrantFiled: August 12, 2014Date of Patent: September 25, 2018Inventor: John Shea
-
Patent number: 10080811Abstract: The present Invention relates to the monitoring of biological substances, such as non-invasive monitoring of such substances in animal, for examples biomarkers and metabolites. Specifically, the invention further relates to such monitoring using rare earth tagged marker compounds. The invention further relates to such monitoring using laser spectroscopy or Raman spectroscopy. The invention further relates to the use of such monitoring in disease states, such as stroke, neurological disorders and cardiovascular disorders.Type: GrantFiled: March 7, 2013Date of Patent: September 25, 2018Assignee: University of LeedsInventors: Sikha Saha, Gin Jose, Animesh Jha
-
Patent number: 10080812Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.Type: GrantFiled: February 24, 2016Date of Patent: September 25, 2018Assignees: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.Inventors: Hideo Saji, Masahiro Ono, Masafumi Ihara, Ikuya Seki
-
Patent number: 10080813Abstract: An apparatus for aseptic insertion includes a container, a first cover, and a second cover. The container includes a first compartment, a second compartment, and a detachable wall disposed between the first compartment and the second compartment. The first cover is sized and configured to attach to the first compartment and the second cover is sized and configured to attach to the container. The detachable wall may defined by a top portion, a portion of a first distal wall of the first compartment, and a portion of a second proximal wall of the second compartment. The detachable wall may be removably attached to the first cover by the top portion of the detachable wall.Type: GrantFiled: June 2, 2011Date of Patent: September 25, 2018Assignee: Ethicon LLCInventors: Kevin D. Felder, Michael J. Stokes, Christopher B. Anderson, Frederick E. Shelton, IV, David C. Yates, John W. Willis, Ashvani K. Madan, Donna L. Korvick
-
Patent number: 10080814Abstract: A method of freshening the air or a surface is provided. The method comprises the steps of: providing a freshening composition, the freshening composition comprising a plurality of particles and a structurant system; and spraying the freshening composition in the form of a plurality of spray droplets, wherein the plurality of spray droplets have: a normalized D(90) value of less than 2.5, when sprayed from a TS800 sprayer according to the SPRAY D(90) NORMALIZED AND SPRAY D(4,3) NORMALIZED TEST METHOD described herein, a residue value of less than about 8 at 5 sprays, according to the RESIDUE TEST METHOD described herein, and a phase stability grade of 1 or 2, according to the PHASE STABILITY GRADE AT 25° C. TEST METHOD described herein.Type: GrantFiled: July 27, 2017Date of Patent: September 25, 2018Assignee: The Procter & Gamble CompanyInventors: Matthew Lawrence Lynch, Carla Jean Colina, Steven Anthony Horenziak, Brandon Philip Illie, Yonas Gizaw
-
Patent number: 10080815Abstract: A system for diffusing one or more volatile compounds includes a base and a pod tray, carried by the base. At least one pod is carried by the pod tray. The pod has a housing holding a volatile compound mass, the housing and mass being moveable relative to one another. An actuator is carried by the base, the actuator being operable to engage the pod and move the housing and the volatile compound mass relative to one another. The pod and the actuator are positionable relative to one another such that one or both of the pod and the actuator can be positioned proximate to one another to enable the actuator to engage the pod and move the housing and the volatile compound mass relative to one another.Type: GrantFiled: December 29, 2015Date of Patent: September 25, 2018Assignee: Henkel IP & Holding GmbHInventors: Keith Cardinal, Kevin Hafer